I. Leonard

833 total citations
9 papers, 513 citations indexed

About

I. Leonard is a scholar working on Oncology, Immunology and Cancer Research. According to data from OpenAlex, I. Leonard has authored 9 papers receiving a total of 513 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 3 papers in Immunology and 3 papers in Cancer Research. Recurrent topics in I. Leonard's work include Lung Cancer Research Studies (4 papers), Immunotherapy and Immune Responses (3 papers) and HER2/EGFR in Cancer Research (3 papers). I. Leonard is often cited by papers focused on Lung Cancer Research Studies (4 papers), Immunotherapy and Immune Responses (3 papers) and HER2/EGFR in Cancer Research (3 papers). I. Leonard collaborates with scholars based in Cuba. I. Leonard's co-authors include Tania Crombet, Agustín Lage, Olga Torres, Mayra Ramos, Rolando Pérez, Elia Neninger, Marta Osorio, René Figueredo, Beatriz García Verdecia and Carmen Viada and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Cancer Biology & Therapy.

In The Last Decade

I. Leonard

7 papers receiving 499 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
I. Leonard Cuba 5 354 185 156 135 114 9 513
Olga Torres Cuba 8 374 1.1× 230 1.2× 140 0.9× 54 0.4× 177 1.6× 12 595
Giselle Saurez Cuba 8 203 0.6× 80 0.4× 223 1.4× 172 1.3× 138 1.2× 11 459
Elia Neninger Cuba 12 453 1.3× 157 0.8× 238 1.5× 370 2.7× 135 1.2× 34 661
Johannes Andel Austria 10 254 0.7× 94 0.5× 95 0.6× 98 0.7× 57 0.5× 30 429
Andy Karabajakian France 9 537 1.5× 246 1.3× 103 0.7× 138 1.0× 42 0.4× 19 684
Talicia Savage United States 8 447 1.3× 110 0.6× 68 0.4× 390 2.9× 67 0.6× 14 617
Elizabeth Gilbert United States 9 523 1.5× 219 1.2× 63 0.4× 85 0.6× 37 0.3× 16 631
David J. Messenheimer United States 3 453 1.3× 90 0.5× 64 0.4× 332 2.5× 47 0.4× 4 549
Kelli L. Running United States 5 412 1.2× 46 0.2× 99 0.6× 367 2.7× 109 1.0× 6 613
W. Jeff Edenfield United States 5 758 2.1× 300 1.6× 117 0.8× 278 2.1× 48 0.4× 5 883

Countries citing papers authored by I. Leonard

Since Specialization
Citations

This map shows the geographic impact of I. Leonard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Leonard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Leonard more than expected).

Fields of papers citing papers by I. Leonard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Leonard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Leonard. The network helps show where I. Leonard may publish in the future.

Co-authorship network of co-authors of I. Leonard

This figure shows the co-authorship network connecting the top 25 collaborators of I. Leonard. A scholar is included among the top collaborators of I. Leonard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Leonard. I. Leonard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Neninger, Elia, Beatriz García Verdecia, Tania Crombet, et al.. (2008). Combining an EGF-based Cancer Vaccine With Chemotherapy in Advanced Nonsmall Cell Lung Cancer. Journal of Immunotherapy. 32(1). 92–99. 53 indexed citations
2.
3.
Crombet, Tania, Mauricio Catalá, Mayra Ramos, et al.. (2006). Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial. Cancer Biology & Therapy. 5(4). 375–379. 124 indexed citations
4.
Neninger, Elia, Tania Crombet, Marta Osorio, et al.. (2005). Vaccination with EGF active immunotherapy improves survival in advanced non small cell lung cancer (NSCLC) patients: Interim analysis of a randomized phase II trial. Journal of Clinical Oncology. 23(16_suppl). 7210–7210. 3 indexed citations
5.
Crombet, Tania, Marta Osorio, Teresa Cruz, et al.. (2004). Use of the Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody h-R3 in Combination With Radiotherapy in the Treatment of Locally Advanced Head and Neck Cancer Patients. Journal of Clinical Oncology. 22(9). 1646–1654. 237 indexed citations
6.
Gonzalez, Gabriela, Carmen Viada, Elia Neninger, et al.. (2004). Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: Analysis of pooled data from three clinical trials. Journal of Clinical Oncology. 22(14_suppl). 2548–2548. 4 indexed citations
7.
Neninger, Elia, Gualberto González‐Sapienza, Tania Crombet, et al.. (2004). Optimized phase I-II trial design for vaccination with epidermal growth factor (EGF): Effect on immunogenicity and safety. Journal of Clinical Oncology. 22(14_suppl). 2610–2610. 3 indexed citations
8.
Gonzalez, Gabriela, Carmen Viada, Elia Neninger, et al.. (2004). Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: Analysis of pooled data from three clinical trials. Journal of Clinical Oncology. 22(14_suppl). 2548–2548.
9.
Crombet, Tania, Elia Neninger, Marta Osorio, et al.. (2004). Vaccination with epidermal growth factor (EGF) for non small cell lung cancer (NSCLC) therapy: Preliminary results from a randomized phase II clinical trial. Journal of Clinical Oncology. 22(14_suppl). 2514–2514. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Olga Torres Breakdown of academic impact, for papers by Giselle Saurez Breakdown of academic impact, for papers by Elia Neninger Breakdown of academic impact, for papers by Johannes Andel Breakdown of academic impact, for papers by Andy Karabajakian Breakdown of academic impact, for papers by Talicia Savage Breakdown of academic impact, for papers by Elizabeth Gilbert Breakdown of academic impact, for papers by David J. Messenheimer Breakdown of academic impact, for papers by Kelli L. Running Breakdown of academic impact, for papers by W. Jeff Edenfield
Rankless by CCL
2026